A Phase 1, Open-Label, Randomized, Cross-Over Study To Estimate The Effects Of PD 0332334 On Lithium Pharmacokinetics In Healthy Subjects.
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 13 Mar 2015
At a glance
- Drugs Imagabalin (Primary) ; Lithium
- Indications Cluster headache; Depression; Generalised anxiety disorder; Mania; Migraine
- Focus Pharmacokinetics
- Sponsors Pfizer
- 26 Feb 2009 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 26 Feb 2009 Actual initiation date (May 2009) added as reported by ClinicalTrials.gov.
- 25 Feb 2009 Pfizer has decided to discontinue development of this drug for the treatment of generalised anxiety disorder, as reported in a media release.